A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies

被引：6
作者：
Haines, Ian E. [1 ]
机构：
[1] Monash Univ, Dept Med, Melbourne Oncol Grp, Melbourne, Vic 3004, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 25期
关键词：
D O I：
10.1200/JCO.2007.12.8421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E31 / E32
页数：2
相关论文
共 30 条
[1]  
[Anonymous], NEW YORK TIMES 0501
[2]  
*ASCO NEWS FOR, 2007, ENS PUBL TRUST JCO A, P44
[3]  
BERENSON A, 2007, NEW YORK TIMES 0425
[4]  
BERENSON A, 2007, NEW YORK TIMES 0509
[5]   A national survey of physician-industry relationships [J].
Campbell, Eric G. ;
Gruen, Russell L. ;
Mountford, James ;
Miller, Lawrence G. ;
Cleary, Paul D. ;
Blumenthal, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (17) :1742-1750
[6]   Following the script: How drug reps make friends and influence doctors [J].
Fugh-Berman, Adriane ;
Ahari, Shahram .
PLOS MEDICINE, 2007, 4 (04) :621-625
[7]   Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].
Giantonio, Bruce J. ;
Catalano, Paul J. ;
Meropol, Neal J. ;
O'Dwyer, Peter J. ;
Mitchell, Edith P. ;
Alberts, Steven R. ;
Schwartz, Michael A. ;
Benson, Al B., III .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544
[8]   Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer [J].
Gordon, MS ;
Margolin, K ;
Talpaz, M ;
Sledge, GW ;
Holmgren, E ;
Benjamin, R ;
Stalter, S ;
Shak, S ;
Adelman, DC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :843-850
[9]  
HARRIS G, 2007, NEW YORK TIMES 0510
[10]  
HARRIS G, 2007, NEW YORK TIMES 0521
123